ArticleScientific reports2025
Malaria infection prevalence and diagnostic performance of the Abbott Bioline Malaria Ag P.f/Pan rapid test in rural populations of Central Cameroon.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
In Cameroon, the management of uncomplicated malaria cases in the communities and in low-resource health facilities rely on the use of reliable rapid diagnostic tests (RDTs). This work was undertaken to determine the trend in human malaria infection in rural settings of Central Cameroon and assess the diagnostic performance of Abbott Bioline Malaria Ag P.f/Pan RDT recommended by the National Malaria Control Programme (NMCP). Cross-sectional surveys were conducted in March 2022 and May 2024. Plasmodium infection was detected using RDT and microscopy techniques, and with real-time PCR for validation of discordant results. Sensitivity (Se), specificity (Sp), positive and negative predictive values, positive and negative likelihood ratios (LR + and LR-), accuracy and agreement were calculated to assess the performance of the RDT. Plasmodium infection prevalence was 64.9% and 71.7% by microscopy and RDT, respectively, Plasmodium falciparum being the predominant species (microscopy:97.48%). With microscopy as reference, the RDT showed high sensitivity (Se:93.37%; CI:91.15%-95.77%) and low specificity (Sp: 68.50%; CI:62.40%-74.17%) for the detection of P. falciparum infection. The positive and negative predictive values were respectively 84.43% (CI:81.01%-87.46%) and 85.71% (CI:80.13%-90.22%). The RDT showed a small positive likelihood ratio (LR + = 2.96; CI:2.47-3.5734), a good negative likelihood ratio (LR-=0.09; CI:0.06-0.13) and moderate agreement (k = 0.652; CI:0.593-0.710; P < 0.001) with microscopy. The RDT showed higher sensitivity (81.48% vs. 48.14%), accuracy (0.75 and vs. 0.50), and agreement (AC1 = 0.715 vs. 0.371) than microscopy. The Abbott Bioline Malaria Ag P.f/Pan RDT demonstrated a high level of agreement with the most sensitive qPCR technique compared to microscopy. These findings further support its use as a reliable malaria diagnostic tool in the highly endemic setting of Central Cameroon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.